Neuland’s Q1 margin slips 4.85 points after Q4 peak
Standalone revenue fell 17.35% QoQ, but operating margin remained 10.87 percentage points above the Healthcare peer median.
Filed 05 Aug 2026, 16:03 IST · after market close · Neuland Laboratories Ltd (NEULANDLAB)
Key takeaways
- Standalone operating margin narrowed 4.85 percentage points QoQ as revenue fell 17.35% while expenses declined only 10.73%.
- Revenue grew 119.16% YoY and operating margin expanded 22.98 percentage points, although the tax rate rose 4.28 percentage points.
- Other income contributed only 4.3% of pre-tax profit, so the quarter's earnings were largely operating-led.
Price around the results
Sequential pullback, sharp YoY improvement
Neuland Laboratories reported standalone revenue growth of 119.16% YoY, while net profit increased 974.84% from a low Q1FY26 base. Sequentially, revenue declined 17.35% and net profit fell 30.66%, reflecting a pullback from the unusually high Q4FY26 base. The company said Q1FY27 was broadly in line with its expectations, with encouraging performance from both CMS and GDS.
Higher costs reduced the Q4 margin peak
QoQ, expenses fell 10.73%, less than the 17.35% decline in revenue, which narrowed operating margin by 4.85 percentage points. On a YoY basis, revenue grew faster than expenses, at 119.16% versus 62.11%, driving a 22.98-percentage-point margin expansion. Interest expense rose 52.18% YoY and the tax rate increased 4.28 percentage points, partly reducing the conversion of operating gains into net profit.
Margin remains above the Healthcare peer median
The 34.69% standalone operating margin was 10.87 percentage points above the 23.82% median for 38 Healthcare peers that had reported the same quarter. The margin had climbed from 11.71% in Q1FY26 to 39.54% in Q4FY26, so the current quarter marks a sequential decline from the peak rather than a reversal of the YoY improvement. Other income was 4.3% of pre-tax profit, keeping reported profit quality primarily operating-led.
Commercial Products led the quarter as projects advanced
Management said Commercial Products contributed most of the quarter's revenue and that the company had 99 active CMS projects, compared with 98 a year earlier. The company told analysts that all significant capex projects were proceeding according to plan and that it expects investment intensity to increase further as opportunities become available. Management also said customer discussions are broadening from individual projects towards wider capability-led engagements.
No immediate market reaction after the post-close filing
The results were filed after market close, so there is no immediate market response to assess. Across eight prior result reactions, the stock rose twice and fell six times, with a median absolute move of 6.77%, providing a history of mostly negative and sizeable moves.
Q1FY27 at a glance
Standalone figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q1FY27 | Q4FY26 | QoQ | YoY |
|---|---|---|---|---|
| Revenue | ₹642 cr | ₹776 cr | -17.35% | +119.16% |
| Other income | ₹8 cr | ₹12 cr | -31.86% | +8.02% |
| Expenses | ₹419 cr | ₹469 cr | -10.73% | +62.11% |
| Operating profit | ₹223 cr | ₹307 cr | -27.47% | +549.11% |
| Operating margin (%) | 34.69% | 39.54% | — | — |
| Interest | ₹7 cr | ₹7 cr | -3.60% | +52.18% |
| Depreciation | ₹27 cr | ₹25 cr | +5.86% | +31.55% |
| Profit before tax | ₹198 cr | ₹287 cr | -31.18% | +1036.59% |
| Tax | ₹50 cr | ₹75 cr | -32.68% | +1267.03% |
| Net profit | ₹147 cr | ₹213 cr | -30.66% | +974.84% |
| EPS (₹) | ₹114.86 | ₹165.65 | -30.66% | +975.47% |
Operating margin of 34.69% compares with a Healthcare sector median of 23.82% across 38 peers that have reported Q1FY27.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- Q1 FY27 was broadly in line with expectations, with encouraging performance from both CMS and GDS businesses.
- Commercial Products contributed most of the quarter's revenue.
- The company had 99 active CMS projects in Q1 FY27, compared with 98 in Q1 FY26.
Guidance & outlook
- Management expects investment intensity to increase further based on available opportunities.
- The company targets 10% women in management by FY 2029-30.
- The company targets women to account for 16% of all hirings by FY 2029-30.
- The company targets more than 90% of business processes digitised across key functions by FY 2029-30.
Expansion
- All significant capex projects are proceeding according to plan.
New initiatives
- The company is engaging customers in broader capability-led discussions rather than only individual projects.
- The company plans a sustainable supply chain roadmap with clearly defined milestones.
What to watch
- Whether standalone operating margin moves back above 34.69% after the 4.85-point QoQ decline.
- Whether active CMS projects increase from 99.
- Whether expenses continue to grow more slowly than revenue, as they did YoY at 62.11% versus 119.16%.